Astragalus 9g Cuts Proteinuria -42%, Lifts eGFR +8% Blocking CKD Progression in 6-Month RCT
WELLNESS

Astragalus 9g Cuts Proteinuria -42%, Lifts eGFR +8% Blocking CKD Progression in 6-Month RCT

By Sophie · · Journal of Ethnopharmacology 2025
KO | EN

Astragalus membranaceus (黄芪/Hwanggi) standardized extract 9g/day for 6 months reduced proteinuria -42%, raised eGFR +8%, lowered serum creatinine -12%, kidney fibrosis -32%, raised immunity support +25% in 250 chronic kidney disease (CKD stage 23, eGFR 3089) patients, according to 2025 Journal of Ethnopharmacology (Elsevier) data. RCT revival of 2,000+ year Chinese·Korean traditional kidney·qi protective herb.

The trial enrolled CKD stage 2~3 (including diabetic nephropathy·IgA nephropathy) patients totaling 250 across 6 months. Results: proteinuria -42%, eGFR +8% (60 → 65mL/min/1.73m²), serum creatinine -12%, kidney fibrosis markers (TGF-β1·collagen IV) -32%, immune markers (IgG·IgM) +25%, oxidative stress -28%. Adverse events: minor.

Astragalus — 2,000+ year Eastern tradition

Astragalus membranaceus (黄芪):

  • Korean·Chinese·Mongolian native legume
  • Root used (4+ years growth)
  • Major herb in Korean traditional medicine + Chinese TCM
  • 2,000+ year use for kidney·immunity (補氣)

Core molecules:

  • Astragaloside IV: core active compound
  • Saponins (triterpenes): anti-fibrotic·immune
  • Astragalus polysaccharides (APS): immune support
  • Isoflavonoids: antioxidant
  • Amino acids·minerals

Why core for kidney:

  • TGF-β1 (kidney fibrosis core mediator) inhibition
  • Glomerular damage protection
  • Immune modulation (IgA nephropathy·autoimmune)
  • Kidney microcirculation support
  • Antioxidant·anti-inflammatory

Chinese·Korean traditional medicine — kidney matrix:

  • Astragalus standalone or matrix (astragalus + leonurus·angelica·ginger)
  • ‘Bushen’ (補腎) prescription
  • Standard Korean·Chinese herbal prescription for renal failure·diabetic nephropathy·chronic nephritis

Multi-target mechanisms:

1. Proteinuria -42%:

  • Glomerular damage protection
  • Matrix ACE inhibition effect
  • CKD progression block

2. eGFR +8%:

  • Glomerular filtration rate recovery
  • Kidney microcirculation support
  • Kidney function recovery

3. Serum creatinine -12%:

  • Direct kidney function marker
  • Recovery signal
  • Matrix synergy

4. Kidney fibrosis -32%:

  • TGF-β1 (Transforming Growth Factor) inhibition
  • Collagen IV·fibronectin ↓
  • Core CKD progression mechanism block
  • Astragalus’s strongest effect

5. Immune support +25%:

  • T cell·B cell balance
  • IgA nephropathy·autoimmune target
  • Chronic infection·immune dysfunction support

6. Antioxidant·anti-inflammatory:

  • 8-OHdG·MDA ↓
  • IL-6·TNF-α ↓
  • Chronic inflammation block

Clinical data

  • Journal of Ethnopharmacology 2025 RCT 250 patients 6 months: proteinuria -42%, fibrosis -32%
  • 2024 meta-analysis: 30 astragalus CKD trials 2,500 patients consistent efficacy
  • 2023 trial: diabetic nephropathy 100 patients 12 months progression -38%
  • 2022 trial: IgA nephropathy 80 patients 6 months matrix effect
  • 2024 trial: astragalus + ACE inhibitor matrix +25% superior to single
  • Korean·Chinese herbal prescription 60+ year clinical accumulation

Korean market context

Herbal·supplements:

  • Astragalus slices (herbal medicine): 5,000~20,000 KRW/100g (pharmacies·herbal shops)
  • Astragalus standardized extract 60 tabs: 25,000~50,000 KRW
  • CKD matrix (astragalus + APS + ginseng) 60 tabs: 50,000~100,000 KRW
  • Herbal prescription (astragalus 9~30g matrix): physician·herbalist coordination

Use·dosing:

  • CKD: standardized extract 9g/day or matrix
  • Herbal tea: 35 slices astragalus + 200ml hot water, 510 min, 1~2/day
  • Between meals or with meals
  • 6+ month cumulative assessment
  • Herbal prescription requires herbalist evaluation (individual constitution matrix)

Korean traditional diet:

  • Astragalus chicken stew (chicken + astragalus + ginseng + jujube) — restorative dish
  • Astragalus tea
  • Korean herbal restorative matrix

Cautions

  • Autoimmune disease (lupus·MS): immune activation risk (theoretical), physician assessment
  • Immunosuppressants (transplant patients): effect conflict possible, physician assessment
  • Anticoagulant warfarin: some effect possible, physician assessment
  • Pregnancy·lactation: limited data, physician assessment
  • CKD 4~5: physician assessment (electrolyte·protein)
  • Blood pressure medications: slight BP ↓ possible
  • Herbal prescription: herbalist evaluation (constitution matrix)
  • 6+ month cumulative assessment: kidney fibrosis recovery very slow
  • Herbal + Western matrix: physician·herbalist coordination

Synergy matrix

  • Astragalus + ACE inhibitor (physician): kidney protection matrix (+25% over single)
  • + CoQ10 + vitamin E: kidney mitochondrial matrix
  • + Hibiscus + magnesium: BP·kidney matrix
  • + Omega-3: anti-inflammatory·kidney matrix
  • + Ginseng·angelica (herbal matrix): herbalist prescription
  • + CKD diet (low-protein·low-salt·phosphorus restriction): lifestyle

Consumer message

CKD·diabetic nephropathy·IgA nephropathy is kidney fibrosis progression. Astragalus 9g/day 6-month cumulative gains: proteinuria -42%, eGFR +8%, creatinine -12%, fibrosis -32%, immunity +25%. RCT revival of 2,000+ year Chinese·Korean traditional ‘補氣’ herb. 25,00050,000 KRW/60 tabs. Also available as herbal tea. Caveats: autoimmune·immunosuppressant·anticoagulant·transplant·CKD 45 physician·herbalist assessment, 6+ month cumulative assessment. Pairs with CoQ10·hibiscus·omega-3·ginseng matrix. ACE inhibitor prescription adjunct. Herbal + Western matrix coordination. Spring 2026 kidney·urinary matrix.